Name | droxidopa |
Synonyms | SM 5688 droxidopa Droxidopa (JAN) threo-Dopaserine beta,3-Dihydroxytyrosine tyrosine, beta,3-dihydroxy- Serine, 3-(3,4-dihydroxyphenyl)- L-threo-3,4-Dihydroxyphenylserine L-Tyrosine, β,3-dihydroxy-, (βR)- L-Tyrosine, b,3-dihydroxy-, threo- (betaS)-beta,3-dihydroxy-D-tyrosine L-threo-b-(3,4-Dihydroxyphenyl)serine Serine, 3-(3,4-dihydroxyphenyl)-, L-threo- (8CI) threo-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid (2S,3S)-2-ammonio-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate |
CAS | 23651-95-8 |
InChI | InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8-/m0/s1 |
Molecular Formula | C9H11NO5 |
Molar Mass | 213.19 |
Density | 1.608±0.06 g/cm3(Predicted) |
Melting Point | 232-235° (dec); mp 229-232° (dec) (Ohashi) |
Boling Point | 549.8±50.0 °C(Predicted) |
Specific Rotation(α) | D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl) |
Flash Point | 286.3°C |
Solubility | DMSO <1 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
Vapor Presure | 6.39E-13mmHg at 25°C |
Appearance | powder |
Color | white to tan |
Merck | 14,3457 |
pKa | 2.09±0.24(Predicted) |
Storage Condition | -20°C |
Stability | Hygroscopic |
Refractive Index | 1.692 |
MDL | MFCD00799030 |
Physical and Chemical Properties | Crystallization from ethanol and diethyl ether, melting point 232-235 °c (decomposition). [Α] D20-39 °(C = 1, 1 mol/L hydrochloric acid). There are also crystals from water and L-ascorbic acid, melting point 229~232 °c (decomposition). [Α] D20-42.0 °(C = 1,1mol/L hydrochloric acid). White to light brown crystalline or crystalline powder, odorless and tasteless. Soluble in dilute hydrochloric acid, insoluble in water, a few insoluble in methanol, ethanol, acetic acid, acetone, chloroform or ether. Acute toxicity LD50 rats and mice (rng/kg):>10000 P. O. Acute toxicity LD50 dog and Rhesus (mg/kg):>5000 Oral. |
In vitro study | Droxidopa is a pro-drug with a similar structure to norepinephrine and contains a carboxyl group. Droxidopa is different from Norepinephrine. It can be taken orally and converted into norepinephrine under the action of DOPA decarboxylase after absorption, so it can increase the content of neurotransmitters. The converted norepinephrine is the same as that in the body. Droxidopa is well tolerated. Droxidopa can act to raise blood pressure in three different ways: a) as a central stimulator of sympathetic activity B) as a peripheral sympathetic neurotransmitter c) as a circulating hormone. Droxidopa alone can increase upright blood pressure. Droxidopa also crosses the blood-brain barrier and is converted to norepinephrine and epinephrine in the brain |
In vivo study | Acute administration of droxidopa in PVL and BDL rats resulted in a significant and sustained increase in arterial blood pressure and mesenteric arterial vascular resistance, and a significant decrease in mesenteric arterial and portal blood flow, without affecting portal pressure and renal blood flow. The ratios of p-eNOS/eNOS and p-AKT/AKT decreased and RhoK activity increased in SMA in Droxidopa-treated rats. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | VT9626010 |
HS Code | 29225090 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.691 ml | 23.453 ml | 46.907 ml |
5 mM | 0.938 ml | 4.691 ml | 9.381 ml |
10 mM | 0.469 ml | 2.345 ml | 4.691 ml |
5 mM | 0.094 ml | 0.469 ml | 0.938 ml |